GHK-Cu Protocol
Copper-binding peptide studied in extracellular-matrix and tissue-remodeling pathways.
- Standard dose
- 1.5 mg
- Frequency
- 1× daily, Daily to 3× weekly depending on route
- Route
- Daily to 3× weekly depending on route
- Cycle
- 8–12 weeks
- Vial
- 50 mg
Evidence Level: Emerging Evidence
Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.
Human evidence: Reasonably substantial topical/cosmetic human trial base; injectable human safety data is comparatively limited.
Animal evidence: Wound-healing and hair-follicle rodent studies support the mechanism.
Introduction & Mechanism of Action
Copper-binding peptide studied in extracellular-matrix and tissue-remodeling pathways.
Naturally occurring copper-binding tripeptide; studied for stimulating collagen/elastin synthesis and modulating matrix metalloproteinase activity in skin and wound models.
Receptors/targets: Not receptor-mediated in the classical sense — acts via copper delivery and matrix-signaling modulation
Areas of Research Interest
- Skin remodeling research
- Extracellular matrix signaling
- Hair and wound biology
Benefits Reported in Research
- Skin-remodeling research
- Wound and matrix-repair studies
- Hair-follicle research
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 1–2 mg
Reported frequency: 1× daily, Daily to 3× weekly depending on route
Reported cycle duration: 8–12 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Research Reference Data
Published research on GHK-Cu reports administration at 1–2 mg via daily to 3× weekly depending on route route. The table below cites that published research — it is not an individualized instruction.
| Variant | Route | Reported frequency | Reported dose |
|---|---|---|---|
| Standard Protocol | Daily to 3× weekly depending on route | 1× daily, Daily to 3× weekly depending on route | 1.5 mg |
Reconstitution Reference
Published research protocols reconstitute a 50 mg vial with 2 mL bacteriostatic water, yielding a concentration of 25.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.
Open the research calculator, pre-filled for GHK-Cu →Research Protocol Timeline
A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.
- 01
Formulation
Supplied as a lyophilized 50 mg vial requiring reconstitution before research use.
- 02
Reconstitution Reference
Published research protocols reconstitute this vial with 2 mL bacteriostatic water to reach 25.00 mg/mL.
- 03
Reported Research Administration
Published research describes 1× daily, daily to 3× weekly depending on route administration via daily to 3× weekly depending on route route, at 1.5 mg per administration.
- 04
Cycle Reference
Published protocols describe a cycle duration of 8–12 weeks. Consult a physician before beginning any new research cycle.
Dilution Guide
Reconstitute with 2 mL bacteriostatic water
Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.
Handling Guide
General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.
Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.
Storage
Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.
Monitoring
Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.
Side Effects
- Injection-site irritation
- Topical redness or sensitivity
Contraindications
- Known copper-metabolism disorders (e.g. Wilson's disease)
- Pregnancy
Drug interactions
- Not well characterized; theoretical interaction with other copper-chelating or copper-containing supplements
Safety
- Copper accumulation theoretical concern with prolonged high-dose use
- Injection-site reactions for the injectable route
Evidence differs sharply by route and formulation. FDA notes limited human safety data for injectable compounded GHK-Cu.
Expected Results & Comparison
GHK-Cu is the common active ingredient inside the blended GLOW and KLOW products — evidence for GHK-Cu alone is stronger than for either blend, since blend-specific combination trials do not exist.